Lingling Xie, Shaodan Lin, Yunyun Liu, Xiaoting Ling, Zhongqiu Lin
{"title":"中国新诊断的晚期卵巢癌维持治疗的前沿：PARP抑制剂的最新证据综述","authors":"Lingling Xie, Shaodan Lin, Yunyun Liu, Xiaoting Ling, Zhongqiu Lin","doi":"10.1111/1471-0528.18180","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>In the first-line (1L) maintenance treatment of newly diagnosed advanced ovarian cancer (OC), poly (ADP-ribose) polymerase inhibitors (PARPi) have demonstrated significant benefits in progression-free survival (PFS) and an encouraging trend in overall survival (OS).</p>\n </section>\n \n <section>\n \n <h3> Objectives</h3>\n \n <p>To provide a summary of advances and evidence regarding the use of PARPi in the maintenance treatment of newly diagnosed advanced OC in the Chinese population.</p>\n </section>\n \n <section>\n \n <h3> Search Strategy</h3>\n \n <p>Systematic search of PubMed from January 2016 to June 2024.</p>\n </section>\n \n <section>\n \n <h3> Selection Criteria</h3>\n \n <p>Phase III randomized trials and real-world studies conducted in China were included.</p>\n </section>\n \n <section>\n \n <h3> Main Results</h3>\n \n <p>PARPi 1L maintenance studies conducted in China have shown that PARPi can prolong PFS in OC patients with manageable safety. Chinese patients differ from foreign patients in baseline characteristics and safety data. Given the current situation of 1L maintenance therapy in China, recommendations are made for maintenance strategies based on different biomarker status.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>PARPi 1L maintenance therapy offers survival benefit to Chinese patients with newly diagnosed advanced OC. OC has become a chronic disease that requires the selection of appropriate maintenance regimens based on multiple factors.</p>\n </section>\n </div>","PeriodicalId":50729,"journal":{"name":"Bjog-An International Journal of Obstetrics and Gynaecology","volume":"132 S4","pages":"5-12"},"PeriodicalIF":4.7000,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Forefront of Maintenance Therapy for Newly Diagnosed Advanced Ovarian Cancer in China: A Review of Updated Evidence With PARP Inhibitors\",\"authors\":\"Lingling Xie, Shaodan Lin, Yunyun Liu, Xiaoting Ling, Zhongqiu Lin\",\"doi\":\"10.1111/1471-0528.18180\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>In the first-line (1L) maintenance treatment of newly diagnosed advanced ovarian cancer (OC), poly (ADP-ribose) polymerase inhibitors (PARPi) have demonstrated significant benefits in progression-free survival (PFS) and an encouraging trend in overall survival (OS).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Objectives</h3>\\n \\n <p>To provide a summary of advances and evidence regarding the use of PARPi in the maintenance treatment of newly diagnosed advanced OC in the Chinese population.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Search Strategy</h3>\\n \\n <p>Systematic search of PubMed from January 2016 to June 2024.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Selection Criteria</h3>\\n \\n <p>Phase III randomized trials and real-world studies conducted in China were included.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Main Results</h3>\\n \\n <p>PARPi 1L maintenance studies conducted in China have shown that PARPi can prolong PFS in OC patients with manageable safety. Chinese patients differ from foreign patients in baseline characteristics and safety data. Given the current situation of 1L maintenance therapy in China, recommendations are made for maintenance strategies based on different biomarker status.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>PARPi 1L maintenance therapy offers survival benefit to Chinese patients with newly diagnosed advanced OC. OC has become a chronic disease that requires the selection of appropriate maintenance regimens based on multiple factors.</p>\\n </section>\\n </div>\",\"PeriodicalId\":50729,\"journal\":{\"name\":\"Bjog-An International Journal of Obstetrics and Gynaecology\",\"volume\":\"132 S4\",\"pages\":\"5-12\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2025-04-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bjog-An International Journal of Obstetrics and Gynaecology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/1471-0528.18180\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bjog-An International Journal of Obstetrics and Gynaecology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/1471-0528.18180","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
The Forefront of Maintenance Therapy for Newly Diagnosed Advanced Ovarian Cancer in China: A Review of Updated Evidence With PARP Inhibitors
Background
In the first-line (1L) maintenance treatment of newly diagnosed advanced ovarian cancer (OC), poly (ADP-ribose) polymerase inhibitors (PARPi) have demonstrated significant benefits in progression-free survival (PFS) and an encouraging trend in overall survival (OS).
Objectives
To provide a summary of advances and evidence regarding the use of PARPi in the maintenance treatment of newly diagnosed advanced OC in the Chinese population.
Search Strategy
Systematic search of PubMed from January 2016 to June 2024.
Selection Criteria
Phase III randomized trials and real-world studies conducted in China were included.
Main Results
PARPi 1L maintenance studies conducted in China have shown that PARPi can prolong PFS in OC patients with manageable safety. Chinese patients differ from foreign patients in baseline characteristics and safety data. Given the current situation of 1L maintenance therapy in China, recommendations are made for maintenance strategies based on different biomarker status.
Conclusions
PARPi 1L maintenance therapy offers survival benefit to Chinese patients with newly diagnosed advanced OC. OC has become a chronic disease that requires the selection of appropriate maintenance regimens based on multiple factors.
期刊介绍：
BJOG is an editorially independent publication owned by the Royal College of Obstetricians and Gynaecologists (RCOG). The Journal publishes original, peer-reviewed work in all areas of obstetrics and gynaecology, including contraception, urogynaecology, fertility, oncology and clinical practice. Its aim is to publish the highest quality medical research in women''s health, worldwide.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
